Karen J. Ferrante - Concepedia

Author

Karen J. Ferrante

Dana-Farber Cancer Institute

Also Known As

K Ferrante, K.J Ferrante, Karen Ferrante, Karen J. Ferrante

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Tokai Pharmaceuticals (United States)The University of Texas Health Science Center at San Antonio Johns Hopkins University Institute of Cancer Research

About

Karen J. Ferrante is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	174
2	Immunology	2	2	41
3	Health Sciences	1	1	30
4	Allergy	1	1	11
5	Molecular Medicine	1	1	30

Karen J. Ferrante

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Journal of Clinical Oncology	2001	997
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma Pedro Sanz-Altamira, Karen J. Ferrante, Roger L. Jenkins, Cancer	1998	86
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Clinical Cancer Research	2015	79
Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer Mary-Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante, European Urology UrologyMedicineHormonal ReceptorPharmacologyResponse—splice Variant	2019	64
A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors Daniel D. Karp, Karen J. Ferrante, Thomas G. Tensfeldt, Lung Cancer MedicineTyrosine KinaseReceptor Tyrosine KinasePharmacologyInhibitor Cp-358,774	2000	58
Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel Manuel Hidalgo, Cheryl Aylesworth, Lisa A. Hammond, Journal of Clinical Oncology	2001	40
Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC). Mary‐Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante, Journal of Clinical Oncology ImmunodeficienciesImmunologyPharmacotherapyPre-clinical PharmacologyClinical Trials	2017	30
A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors André Planting, Ate van der Gaast, Patrick Schöffski, Cancer Chemotherapy and Pharmacology MedicinePharmacologyPathologyAdvanced Solid TumorsAnti-cancer Agent	2004	11
The plasma corticosteroid profile in the adjuvant induced arthritic rat model James F. Belliveau, David M. Tschaen, Karen J. Ferrante, FEBS Letters InflammationRheumatoid DisorderAnti-inflammatoryAutoimmune DiseaseAllergy	1982	11

Page 1